Synairgen (LON:SNG) Shares Cross Below 200-Day Moving Average of $14.31
Synairgen (LON:SNG) Shares Cross Below 200-Day Moving Average of $14.31
Synairgen plc (LON:SNG – Get Rating) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 14.31 ($0.18) and traded as low as GBX 9.50 ($0.12). Synairgen shares last traded at GBX 9.50 ($0.12), with a volume of 377,264 shares trading hands.
Synairgen plc(倫敦股票代碼：SNG-GET)在週五的交易中跌破200日移動均線。該股的200日移動均線為14.31英鎊(合0.18美元)，交易價格低至9.50英鎊(合0.12美元)。Synairgen的股票最新報9.50英鎊(合0.12美元)，成交量為377,264股。
Synairgen Stock Performance
Synairgen股票表現
The company has a debt-to-equity ratio of 0.09, a current ratio of 6.35 and a quick ratio of 6.35. The stock has a 50 day simple moving average of GBX 10.58 and a two-hundred day simple moving average of GBX 14.31. The company has a market cap of £19.13 million, a PE ratio of -55.88 and a beta of -2.29.
該公司的債務權益比為0.09，流動比率為6.35，速動比率為6.35。該股的50日簡單移動均線切入位為10.58英鎊，200日簡單移動均線切入位為14.31英鎊。該公司市值為1913萬GB，本益比為-55.88，貝塔係數為-2.29。
Synairgen Company Profile
Synairgen公司簡介
(Get Rating)
(獲取評級)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Synairgen plc發現和開發治療呼吸系統疾病的藥物。該公司開發的產品有：治療新冠肺炎的乙型吸入型幹擾素SG001；治療感冒和流感引起的哮喘的乙型幹擾素吸入劑；治療或預防慢性阻塞性肺病的乙型幹擾素第二階段臨床試驗；以及治療特發性肺纖維化的LXL2抑制劑。
Featured Stories
專題報道
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
- ExxonMobil Gushes To New Highs
- 如何投資今年最受歡迎的食品雜貨股
- 陣列技術將太陽耀斑帶到2023年收益預測
- 利率上升前最適合投資的銀行股
- 如何投資農田：7個簡單的方法
- 埃克森美孚股價創新高
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synairgen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synairgen和相關公司的最新新聞和分析師評級的每日簡明摘要。